This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Valeant Pharmaceuticals International, Inc.
Drug Names(s): efinaconazole, KP-103, IDP-108
Description: IDP-108 is a topical triazole antifungal.
Triazole antifungals inhibit the fungal cytochrome P450 enzyme 14alpha-demethlyase, thus preventing the conversion of lanosterol to ergosterol, an essential component of the fungal cytoplasmic membrane.
Deal Structure: IDP-108 was licensed by Dow Pharmaceutical Sciences from Kaken Pharmaceuticals.
In January 2010, Valeant acquired Dow Pharmaceutical Sciences. Dow Pharmaceutical will operate as a wholly owned subsidiary of Valeant. Kaken retained rights to the compound in Japan.
Partners: Kaken Pharmaceutical Company, Ltd
Additional information available to subscribers only: